Women account for an estimated 56% of total US healthcare spending by 2030, according to actuarial modeling by Deloitte. The firm's report models $527 billion in additional potential spending on US women's health that year - the delta between a baseline trajectory and a scenario in which care shifts toward earlier detection and prevention. The report is a vendor analysis with commercial interests behind it, but its clinical findings draw on peer-reviewed research and federal health data that independently support the same underlying conclusion.
Women's health in employer plan design has historically meant maternity and reproductive coverage. The conditions with the largest long-term cost implications - cardiovascular disease, musculoskeletal disorders, autoimmune conditions - are not reproductive. They build across decades and tend to accelerate at the menopausal transition, in midlife, and in the years that follow.
Heart disease affects approximately 60 million US women, or roughly 44% of the female population, according to the American Heart Association's 2026 statistics. In 2023, it accounted for approximately one-in-five deaths among women in the US, based on separate data from Centers for Disease Control and Prevention.
The clinical picture behind those numbers is less familiar. Cardiovascular risk in women builds differently than in men, accelerating during the menopausal transition as estrogen decline affects metabolic and vascular function. Hypertensive disorders of pregnancy, including preeclampsia, are associated with elevated long-term cardiovascular risk. Heart attacks in women can present with symptoms less recognizable as cardiac in origin, which increases the likelihood of delayed diagnosis and intervention.
The practical implication sits in that last point. Sex-specific diagnostics - AI-enabled cardiovascular imaging embedded in routine mammography workflows, blood-based biomarkers now capable of predicting 30-year cardiovascular risk - are entering clinical use, but coverage decisions tend to lag the evidence. An employer health plan that last reviewed its preventive cardiovascular coverage before the current generation of sex-specific diagnostic tools became available may be operating on five-year-old assumptions.
Musculoskeletal and autoimmune conditions are where the coverage gap and the claims cost connect most directly. Osteopenia affects an estimated 27.3 million US women, and women over 50 face roughly a one-in-three remaining lifetime risk of an osteoporotic fracture, according to the Deloitte report citing National Osteoporosis Foundation data.
Rheumatoid arthritis, which affects women at a lifetime risk of 3.6%, also carries a 68% higher risk of myocardial infarction and a 41% higher stroke risk among those diagnosed, per peer-reviewed research cited in the Deloitte report.
The cost sequence is predictable. Undetected bone loss leads to fractures while unmanaged rheumatoid arthritis compounds cardiovascular exposure. Employer plans covering musculoskeletal conditions are often paying for acute episodes - the fracture, the joint replacement, the flare - rather than the earlier detection that could have reduced their probability.
An FDA 510(k)-cleared tool that screens routine hip X-rays for low bone density in patients over 50 now exists. Whether employer plans are covering the follow-up care a positive finding triggers is a renewal conversation, not a clinical one.
Employer-sponsored insurance covers approximately 59.7 million US women ages 19 to 64, according to a June Kaiser Family Foundation fact sheet, representing about 60% of women in that age range.
A Business Group on Health employer survey, meanwhile, found that 58% of employers plan to expand preventive care for women in 2026, up 22 percentage points over two years, and that menopause-specific programs have grown from 28% of employers in 2024 to 58% in 2026.
The movement is real but uneven. The Business Group on Health figures skew toward large employers. Mid-size and smaller employers tend to move more slowly on benefit design changes.
The conditions the Deloitte report highlights - cardiovascular risk that peaks post-menopause, bone loss that accelerates in the 50s, autoimmune disorders that can begin in the 30s - affect women across the workforce, not only those at organizations that have made women's health a declared priority.
With employer health benefit costs projected to rise 8.2% in 2027, the steepest increase in 24 years, the benefit design conversation is increasingly framed around cost containment. The Deloitte model's argument is that the framing is backward: care that reaches women before cardiovascular risk becomes cardiovascular disease, or before bone loss becomes fracture, costs less downstream than care that treats the outcome.
That argument is not new, but it now has actuarial modeling and a growing set of FDA-cleared diagnostic tools behind it. Coverage decisions at the next renewal will determine how much of that evidence actually reaches employees.
